| Today's Top Story |  |  | | - Bristol, Santaris to develop RNA drugs in deal with $100M potential
Bristol-Myers Squibb and Santaris Pharma, which specializes in developing drugs against mRNA and microRNA targets, agreed to collaborate in the discovery and development of drugs using the latter's locked nucleic acid drug technology. Santaris will get research and discovery funding, as well as a $10 million upfront payment from Bristol. The deal also entitles Santaris to as much as $90 million in milestone fees per product plus sales royalties. Genetic Engineering & Biotechnology News (4/16)       | Health Care & Policy | | | | - Agila, Pfenex sign biosimilar joint venture deal
Pfenex and Agila Biotech agreed to develop, manufacture and market six biosimilars as part of a joint venture. Pfenex will combine its strain engineering and process development know-how with Agila's biologics production and clinical development expertise. The venture's lead product will be interferon beta-1b, a biosimilar version of multiple sclerosis treatment Betaseron. Genetic Engineering & Biotechnology News (4/16) - Acorda plans to develop MS drug for post-stroke indication
Acorda Therapeutics plans to continue developing its multiple sclerosis drug Ampyra, or dalfampridine, against stroke-related disability after obtaining positive results from a Phase II trial. Ampyra significantly improved the walking speed of patients who had an ischemic stroke. Ampyra was approved by the FDA in 2010 for patients with multiple sclerosis. PharmaTimes (U.K.) (4/16) - FDA rejects migraine drug inhaler from Allergan
Allergan failed to obtain FDA approval for Levadex, an inhaled version of the migraine drug dihydroergotamine. The FDA voiced concerns about the production process for the drug's canister. Allergan said it will address the issues raised by the agency. Reuters (4/16) | Company & Financial News | | | | - Ares bolsters immunotherapy business with Antigen Lab acquisition
Switzerland's Ares Life Sciences agreed to purchase the complete share capital of Planet Biopharmaceuticals including its Antigen Laboratories unit, which makes allergen extracts for ear, nose and throat specialists in the U.S. The deal supports Ares' strategic focus on the allergy immunotherapy market, a company official said. "We view the acquisition of Antigen as very complementary to our other investments in the allergy market," said Ares CEO Jacques Theurillat. Pharmaceutical Business Review Online (4/16) - MJ Fox Foundation grants $750K for drug delivery research
The Michael J. Fox Foundation granted Intec Pharma $750,000 for commercialization of an extended release delivery system for Levodopa, the leading treatment for Parkinson's disease. Levodopa does not last long in the blood stream, so finding a way to extend the release of the drug can provide an alternative to giving it in large doses, which comes with side effects. MedCityNews.com (4/14) | Food & Agriculture | | | | - Gene-editing method used in pig, research team says
Scientists at the Roslin Institute in Scotland said they have developed a disease-resistant pig using a new gene-editing method. The pig is part of a research project seeking to create infection-resistant animals. The gene-editing technique is more efficient than standard methods and can be used on fertilized eggs, said Bruce Whitelaw of the institute. Daily Mercury (Mackay, Australia) (4/17) | Industrial & Environmental | | | | - Report: U.S. leads in cellulosic ethanol production
The U.S. is the top producer of cellulosic ethanol, with 5.42 million gallons in 2012, according to a report by GlobalData. The country's top ranking could be related to federal grants that support the biofuel, as well as the abundance of feedstock supply in the U.S. Worldwide, cellulosic production reached 14.25 million gallons last year and is expected to rise to 412.25 million gallons by 2020. Energy Digital (4/15) | News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | Besides the noble art of getting things done, there is the noble art of leaving things undone. The wisdom of life consists in the elimination of non-essentials."
--Lin Yutang,
Chinese writer, translator, linguist and inventor  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, April 16, 2013
- Monday, April 15, 2013
- Friday, April 12, 2013
- Thursday, April 11, 2013
- Wednesday, April 10, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment